Last reviewed · How we verify
NCT04176315: REHIP
Usability and Effectiveness of ReHub in Patients After Total Hip Arthroplasty
NA trial testing Conventional Home-based Rehabilitation Plan in Hip Osteoarthritis in 38 participants. Terminated before completion.
19 December 2020
Quick facts
| Lead sponsor | Bio-Sensing Solutions S.L. (DyCare) |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 38 |
| Start date | 4 December 2019 |
| Primary completion | 19 December 2020 |
| Estimated completion | 19 December 2020 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Conventional Home-based Rehabilitation Plan
- ReHub Home-based Rehabilitation Plan
Conditions studied
- Hip Osteoarthritis — all drugs for Hip Osteoarthritis →
Sponsor
Bio-Sensing Solutions S.L. (DyCare)
Who can join
Adults 60 to 80, any sex, with Hip Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, non-blinded, parallel assignment, clinical trial for the evaluation of usability and effectiveness of ReHub, a telerehabilitation system made up of a cloud platform and an exercise kit with smart sensors, for performing rehabilitation exercises after a primary Total Hip Arthroplasty (THA). Patients admitted to Presidio San Camillo after a THA surgery are randomly allocated to the control arm or the experimental arm with a 1:1 ratio. Participants in both arms receive inpatient care and rehabilitation for 2 weeks at San Camillo. At discharge, they are prescribed with the same daily plan of 5 exercises for autonomous home-based rehabilitation. The experimental arm participants use ReHub to do their exercises instead of working independently and physiotherapists monitor their performance and adherence remotely. Outcomes assessment is performed at San Camillo admission (baseline), at San Camillo discharge (2 weeks from baseline) and 3 weeks after San Camillo discharge (5 weeks from baseline).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Effectiveness of a home-based telerehabilitation system in patients after total hip arthroplasty: study protocol of a randomized controlled trial.
Busso C, Castorina G, Di Monaco M, Rodriguez D, et al · · 2020 · cited 7× · PMID 33054811 · DOI 10.1186/s13063-020-04791-4 -
Effectiveness of A Home-Based Telerehabilitation System in Patients After Total Hip Arthroplasty: Study Protocol of A Randomized Controlled Trial
Busso C, Castorina G, Monaco MD, Rodriguez D, et al · · 2020 · DOI 10.21203/rs.3.rs-36194/v1
Verify or expand the search:
- PubMed search for NCT04176315
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hip Osteoarthritis
Currently open trials in the same condition.
- NCT07330999 — Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults · NA · recruiting
- NCT07327931 — PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults · NA · recruiting
- NCT07288983 — PENG Block vs Suprainguinal FICB vs Lumbar ESPB for Analgesia After Hip Surgery · NA · recruiting
- NCT07327372 — PENG Block With Dexmedetomidine in Older Adults · NA · recruiting
- NCT07347041 — Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Hip Osteoarthritis(OA) · NA · recruiting
Other Bio-Sensing Solutions S.L. (DyCare) trials
Trials by the same sponsor.
- NCT04155957 — Evaluation of Safety and Efficacy of ReHub in Patients Who Underwent Primary Total Knee Arthroplasty · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04176315 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bio-Sensing Solutions S.L. (DyCare)
- Last refreshed: 9 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04176315.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing